[
    [
        {
            "time": "",
            "original_text": "【国盛证券张金洋团队】恒瑞医药：两大品种申报上市，研管线超预期推进",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "两大品种",
                    "申报上市",
                    "研管线",
                    "超预期推进"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛证券张金洋团队】恒瑞医药：两大品种申报上市，研管线超预期推进",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]